^
    Back
    Association details:
    Biomarker:PARP1 mutation
    Cancer:Solid Tumor
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Cancer Genet
    Title:

    DNA repair and immune checkpoint blockade response

    Published date:
    02/24/2022
    Excerpt:
    Here, we examined the association between mutations in 25 core DNA repair genes and ICB outcomes in 6619 patients across 9 cancer types with advanced disease and MSK-IMPACT tumor sequencing. Notably, we observed that mutations in 7 of the DNA repair genes (ATM, ATR, POLE, ERCC4, NBN, RAD50, PARP1) were significantly associated with improved overall survival in ICB-treated patients (p < 0.05 for all)...
    DOI:
    10.1016/j.cancergen.2022.02.007